Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEVATE-LTE long-term extension in Duchenne muscular dystrophy
2025-525124-10-00Phase 2Authorised
- Sponsor
- Entrada Therapeutics
- Start
- Jul 2026
- Modality
- Gene Therapies, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label trial of ENTR-601-44 and ENTR-601-45 in Duchenne muscular dystrophy (DMD) (2 arms), sponsored by Entrada Therapeutics. Primary endpoints: Incidence and severity of treatment-emergent adverse events, Change in vital signs and 3 more. Planned start Jul 2026; status: authorised.
02
Drugs
ENTR-601-44ENTR-601-45
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2025-525124-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525124-10-00.